Known targets — ChEMBL curated mechanism
DHFRGARTPTGFRPTGIRPTGS1PTGS2TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8envmurAthyA
The experimentally established mechanism targets of Tromethamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 2/20 | 0.36 |
| ▸ | GABRD | O14764 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tromethamine SCHEMBL30296964 | 0.87 | MEN1 (0.53) | MEN1LMNAKMT2ASLC7A5SLC1A3 | |
| Tromethamine SCHEMBL28614671 | 0.85 | TP53 (0.55) | MEN1LMNAKMT2ASLC7A5GABRR1 | |
| Valine SCHEMBL9234038 | 0.84 | SLC7A5 (0.65) | MEN1LMNAKMT2ASLC7A5SLC1A3 | |
| Valine SCHEMBL3511172 | 0.84 | SLC7A5 (0.65) | MEN1LMNAKMT2ASLC7A5SLC1A3 | |
| Threonine SCHEMBL4335256 | 0.82 | SLC7A5 (0.44) | MEN1LMNAKMT2ASLC7A5SLC1A3 | |
| Alanine SCHEMBL15657545 | 0.81 | SLC7A5 (0.46) | SLC7A5SLC1A3SLC1A2SLC1A1LTA4H | |
| Alanine SCHEMBL15658201 | 0.81 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2SLC1A1LTA4H | |
| Alanine SCHEMBL9397402 | 0.78 | — | — | |
| Tromethamine SCHEMBL7347818 | 0.78 | LMNA (0.62) | MEN1LMNAKMT2AALDH1A1 | |
| Tromethamine SCHEMBL194002 | 0.78 | LMNA (0.62) | MEN1LMNAKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070148629-A1 | Composition for the preservation of viruses | SETIAWAN KERRIE | 2007-06-28 | — | — | US | disclosed |
| EP-0777679-B1 | DELIVERY OF NUCLEIC ACIDS | COMMW SCIENT IND RES ORG (AU) | 2003-11-05 | — | — | EP | disclosed |
| US-5906922-A | EXPOSING THE CELL WITH A PEPTIDENUCLEIC ACID; USEFUL FOR DELIVERING DNA OR RNA | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1999-05-25 | — | — | US | disclosed |
| EP-0777679-A4 | DELIVERY OF NUCLEIC ACIDS | COMMW SCIENT IND RES ORG (AU) | 1997-10-08 | — | — | EP | disclosed |
| EP-0777679-A1 | DELIVERY OF NUCLEIC ACIDS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996005218-A1 | DELIVERY OF NUCLEIC ACIDS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1996-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070148629-A1 | Composition for the preservation of viruses | PRNP, PLIN3, PHOSPHO1 | PTGS1 4442/4885MEN1 3090/4885LMNA 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.